Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability, 55435-55438 [2022-19491]
Download as PDF
Federal Register / Vol. 87, No. 174 / Friday, September 9, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: a testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product, ORILISSA
(elagolix sodium) indicated for the
management of moderate to severe pain
associated with endometriosis.
Subsequent to this approval, the USPTO
received patent term restoration
applications for ORILISSA (U.S. Patent
Nos. 7,056,927 and 7,419,983) from
Neurocrine Biosciences, Inc. and the
USPTO requested FDA’s assistance in
determining the patents’ eligibility for
patent term restoration. In a letter dated
October 29, 2019, FDA advised the
USPTO that this human drug product
had undergone a regulatory review
period and that the approval of
ORILISSA represented the first
permitted commercial marketing or use
of the product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
ORILISSA is 5,452 days. Of this time,
5,117 days occurred during the testing
phase of the regulatory review period,
while 335 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C.
355(i)) became effective: August 21,
VerDate Sep<11>2014
18:57 Sep 08, 2022
Jkt 256001
2003. FDA has verified the applicant’s
claim that the date the investigational
new drug application became effective
was on August 21, 2003.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the FD&C Act: August 23,
2017. FDA has verified the applicant’s
claim that the new drug application
(NDA) for ORILISSA (NDA 210450) was
initially submitted on August 23, 2017.
3. The date the application was
approved: July 23, 2018. FDA has
verified the applicant’s claim that NDA
210450 was approved on July 23, 2018.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its applications for patent extension,
this applicant seeks 5 years of patent
term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: August 30, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–19506 Filed 9–8–22; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
55435
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–0150]
Revocation of Two Authorizations of
Emergency Use of In Vitro Diagnostic
Devices for Detection and/or Diagnosis
of COVID–19; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
revocation of the Emergency Use
Authorizations (EUAs) (the
Authorizations) issued to Becton,
Dickinson and Company (BD) for the BD
SARS-CoV–2/Flu for BD MAX System,
and Talis Biomedical Corporation
(Talis) for the Talis One COVID–19 Test
System. FDA revoked these
Authorizations under the Federal Food,
Drug, and Cosmetic Act (FD&C Act).
The revocations, which include an
explanation of the reasons for each
revocation, are reprinted in this
document.
DATES: The Authorization for the BD
SARS-CoV–2/Flu for BD MAX System is
revoked as of August 1, 2022. The
Authorization for the Talis One COVID–
19 Test System is revoked as of August
23, 2022.
ADDRESSES: Submit written requests for
a single copy of the revocations to the
Office of Counterterrorism and
Emerging Threats, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4338, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request or
include a fax number to which the
revocations may be sent. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the revocations.
FOR FURTHER INFORMATION CONTACT:
Jennifer J. Ross, Office of
Counterterrorism and Emerging Threats,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 1, Rm.
4332, Silver Spring, MD 20993–0002,
301–796–8510 (this is not a toll-free
number).
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Section 564 of the FD&C Act (21
U.S.C. 360bbb–3) as amended by the
Project BioShield Act of 2004 (Pub. L.
108–276) and the Pandemic and AllHazards Preparedness Reauthorization
Act of 2013 (Pub. L. 113–5) allows FDA
to strengthen the public health
E:\FR\FM\09SEN1.SGM
09SEN1
55436
Federal Register / Vol. 87, No. 174 / Friday, September 9, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES
protections against biological, chemical,
nuclear, and radiological agents. Among
other things, section 564 of the FD&C
Act allows FDA to authorize the use of
an unapproved medical product or an
unapproved use of an approved medical
product in certain situations. On
February 10, 2021, FDA issued an EUA
to BD for the BD SARS–CoV–2/Flu for
BD MAX System, subject to the terms of
the Authorization. Notice of the
issuance of this Authorization was
published in the Federal Register on
April 23, 2021 (86 FR 21749), as
required by section 564(h)(1) of the
FD&C Act. On November 5, 2021, FDA
issued an EUA to Talis for the Talis One
COVID–19 Test System, subject to the
terms of the Authorization. Notice of the
issuance of this Authorization was
published in the Federal Register on
March 22, 2022 (87 FR 16196), as
required by section 564(h)(1) of the
FD&C Act. Subsequent updates to the
Authorizations were made available on
FDA’s website. The authorization of a
device for emergency use under section
564 of the FD&C Act may, pursuant to
section 564(g)(2) of the FD&C Act, be
VerDate Sep<11>2014
18:57 Sep 08, 2022
Jkt 256001
revoked when the criteria under section
564(c) of the FD&C Act for issuance of
such authorization are no longer met
(section 564(g)(2)(B) of the FD&C Act),
or other circumstances make such
revocation appropriate to protect the
public health or safety (section
564(g)(2)(C) of the FD&C Act).
II. EUA Revocation Requests
In a request received by FDA on July
26, 2022, BD requested withdrawal of,
and effective August 1, 2022, FDA
revoked, the Authorization for the BD
SARS–CoV–2/Flu for BD MAX System.
Because BD notified FDA that BD has
discontinued the sale of the BD SARS–
CoV–2/Flu for BD MAX System and
requested FDA to withdraw the
authorization of the BD SARS–CoV–2/
Flu for BD MAX System, FDA has
determined that it is appropriate to
protect the public health or safety to
revoke this Authorization.
In a request received by FDA on
August 12, 2022, Talis requested
revocation of, and on August 23, 2022,
FDA revoked, the Authorization for the
Talis One COVID–19 Test System.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Because Talis notified FDA that Talis
has not commercially distributed the
authorized product in the United States
and requested FDA revoke the
authorization of the Talis One COVID–
19 Test System, FDA has determined
that it is appropriate to protect the
public health or safety to revoke this
Authorization.
III. Electronic Access
An electronic version of this
document and the full text of the
revocations are available on the internet
at https://www.regulations.gov/.
IV. The Revocations
Having concluded that the criteria for
revocation of the Authorizations under
section 564(g)(2)(C) of the FD&C Act are
met, FDA has revoked the EUA of BD
for the BD SARS–CoV–2/Flu for BD
MAX System and of Talis for the Talis
One COVID–19 Test System. The
revocations in their entirety follow and
provide an explanation of the reasons
for each revocation, as required by
section 564(h)(1) of the FD&C Act.
BILLING CODE 4164–01–P
E:\FR\FM\09SEN1.SGM
09SEN1
VerDate Sep<11>2014
18:57 Sep 08, 2022
Jkt 256001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4725
E:\FR\FM\09SEN1.SGM
09SEN1
55437
EN09SE22.044
jspears on DSK121TN23PROD with NOTICES
Federal Register / Vol. 87, No. 174 / Friday, September 9, 2022 / Notices
55438
Dated: September 2, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–19491 Filed 9–8–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–D–1837]
BILLING CODE 4164–01–C
jspears on DSK121TN23PROD with NOTICES
Statement of Identity and Strength—
Content and Format of Labeling for
Human Nonprescription Drug
Products; Draft Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
SUMMARY:
VerDate Sep<11>2014
18:57 Sep 08, 2022
Jkt 256001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
‘‘Statement of Identity and Strength—
Content and Format of Labeling for
Human Nonprescription Drug
Products.’’ This draft guidance provides
recommendations for the content and
format of the required statement of
identity on the labeling of human
nonprescription drug products. This
draft guidance also provides
recommendations on the inclusion of
the drug product’s strength on the
labeling. The recommendations in this
draft guidance are intended to help
manufacturers, packers, distributors,
applicants, relabelers, and sponsors
ensure consistent content and format of
the statement of identity and strength
for all human nonprescription drug
products. Consistent content and format
E:\FR\FM\09SEN1.SGM
09SEN1
EN09SE22.045
Federal Register / Vol. 87, No. 174 / Friday, September 9, 2022 / Notices
Agencies
[Federal Register Volume 87, Number 174 (Friday, September 9, 2022)]
[Notices]
[Pages 55435-55438]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-19491]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0150]
Revocation of Two Authorizations of Emergency Use of In Vitro
Diagnostic Devices for Detection and/or Diagnosis of COVID-19;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
revocation of the Emergency Use Authorizations (EUAs) (the
Authorizations) issued to Becton, Dickinson and Company (BD) for the BD
SARS-CoV-2/Flu for BD MAX System, and Talis Biomedical Corporation
(Talis) for the Talis One COVID-19 Test System. FDA revoked these
Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C
Act). The revocations, which include an explanation of the reasons for
each revocation, are reprinted in this document.
DATES: The Authorization for the BD SARS-CoV-2/Flu for BD MAX System is
revoked as of August 1, 2022. The Authorization for the Talis One
COVID-19 Test System is revoked as of August 23, 2022.
ADDRESSES: Submit written requests for a single copy of the revocations
to the Office of Counterterrorism and Emerging Threats, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4338, Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request or include a fax number to which
the revocations may be sent. See the SUPPLEMENTARY INFORMATION section
for electronic access to the revocations.
FOR FURTHER INFORMATION CONTACT: Jennifer J. Ross, Office of
Counterterrorism and Emerging Threats, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 1, Rm. 4332, Silver Spring, MD 20993-
0002, 301-796-8510 (this is not a toll-free number).
SUPPLEMENTARY INFORMATION:
I. Background
Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the
Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and
All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5)
allows FDA to strengthen the public health
[[Page 55436]]
protections against biological, chemical, nuclear, and radiological
agents. Among other things, section 564 of the FD&C Act allows FDA to
authorize the use of an unapproved medical product or an unapproved use
of an approved medical product in certain situations. On February 10,
2021, FDA issued an EUA to BD for the BD SARS-CoV-2/Flu for BD MAX
System, subject to the terms of the Authorization. Notice of the
issuance of this Authorization was published in the Federal Register on
April 23, 2021 (86 FR 21749), as required by section 564(h)(1) of the
FD&C Act. On November 5, 2021, FDA issued an EUA to Talis for the Talis
One COVID-19 Test System, subject to the terms of the Authorization.
Notice of the issuance of this Authorization was published in the
Federal Register on March 22, 2022 (87 FR 16196), as required by
section 564(h)(1) of the FD&C Act. Subsequent updates to the
Authorizations were made available on FDA's website. The authorization
of a device for emergency use under section 564 of the FD&C Act may,
pursuant to section 564(g)(2) of the FD&C Act, be revoked when the
criteria under section 564(c) of the FD&C Act for issuance of such
authorization are no longer met (section 564(g)(2)(B) of the FD&C Act),
or other circumstances make such revocation appropriate to protect the
public health or safety (section 564(g)(2)(C) of the FD&C Act).
II. EUA Revocation Requests
In a request received by FDA on July 26, 2022, BD requested
withdrawal of, and effective August 1, 2022, FDA revoked, the
Authorization for the BD SARS-CoV-2/Flu for BD MAX System. Because BD
notified FDA that BD has discontinued the sale of the BD SARS-CoV-2/Flu
for BD MAX System and requested FDA to withdraw the authorization of
the BD SARS-CoV-2/Flu for BD MAX System, FDA has determined that it is
appropriate to protect the public health or safety to revoke this
Authorization.
In a request received by FDA on August 12, 2022, Talis requested
revocation of, and on August 23, 2022, FDA revoked, the Authorization
for the Talis One COVID-19 Test System. Because Talis notified FDA that
Talis has not commercially distributed the authorized product in the
United States and requested FDA revoke the authorization of the Talis
One COVID-19 Test System, FDA has determined that it is appropriate to
protect the public health or safety to revoke this Authorization.
III. Electronic Access
An electronic version of this document and the full text of the
revocations are available on the internet at https://www.regulations.gov/.
IV. The Revocations
Having concluded that the criteria for revocation of the
Authorizations under section 564(g)(2)(C) of the FD&C Act are met, FDA
has revoked the EUA of BD for the BD SARS-CoV-2/Flu for BD MAX System
and of Talis for the Talis One COVID-19 Test System. The revocations in
their entirety follow and provide an explanation of the reasons for
each revocation, as required by section 564(h)(1) of the FD&C Act.
BILLING CODE 4164-01-P
[[Page 55437]]
[GRAPHIC] [TIFF OMITTED] TN09SE22.044
[[Page 55438]]
[GRAPHIC] [TIFF OMITTED] TN09SE22.045
Dated: September 2, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-19491 Filed 9-8-22; 8:45 am]
BILLING CODE 4164-01-C